



## Update on the HPV vaccination for men who have sex with men (MSM) pilot in England

The HPV for MSM pilot is currently underway. It began rolling out from June 2016 in two GUM clinics, and 13 more clinics have since joined the pilot and are starting to deliver the vaccine as soon as all necessary systems are in place. PHE is currently in the process of confirming participation from further GUM and HIV clinics. Clinic participation in the pilot is by invitation and is based on geographic spread.

Currently HPV vaccination for MSM in England is only available through the pilot. This is a targeted pilot aimed at MSM up to 45 years of age who are already attending GUM and HIV clinics for other health care where they will be offered the vaccine opportunistically during existing appointments.

The cost-effectiveness analysis on which the JCVI based its advice<sup>1</sup> only considered those MSM who are already attending GUM and HIV clinics, who are assumed to be at higher risk within the MSM population in terms of risk behaviour and STI transmission.

The purpose of the pilot is to answer questions about the feasibility, cost-effectiveness and equity of a national programme offering the vaccine in this setting. In order to prevent distorting the results of the pilot and to allow an unbiased assessment of its effectiveness, MSM should not be actively encouraged to attend clinics specifically for HPV vaccination during the pilot phase. PHE is not actively promoting the availability of HPV vaccination at these clinics during the pilot. Increased clinic attendances and associated costs due to MSM attending pilot clinics only for HPV vaccination, or attending clinics that they otherwise wouldn't normally attend, could distort the evaluation of the pilot.

A national patient leaflet has been produced for participating clinics to give to MSM being offered the vaccine.


Enquiries on the HPV-MSM pilot should be sent to [immunisation@phe.gov.uk](mailto:immunisation@phe.gov.uk)

---

<sup>1</sup> JCVI advice on HPV vaccination for MSM, November 2015:

<https://www.gov.uk/government/publications/jcvi-statement-on-hpv-vaccination-of-men-who-have-sex-with-men>

## Resources



### Immunising preschool children against flu

A briefing on vaccinating preschool children against flu, aimed at practitioners working in the early years settings, is available to download from [web link 1](#).

It is for nursery and preschool managers and staff, and childminders delivering the Early Years Foundation Stage Framework and those who provide informal childcare, such as nannies. It sets out the background to the programme and how they can support it, including resources available to download.



### Helping stop you getting flu: information for children with learning disabilities

Following the popularity of the easyread leaflet produced about flu immunisation for people with learning disabilities, a revised version aimed at children is now available.

This explains why children with learning disabilities are being offered the nasal spray vaccine and can be downloaded for free from [web link 2](#).

### Letter template to invite those with learning disabilities for flu vaccination

A letter template for GP practices to use to invite patients who are eligible for flu vaccination because they have a learning disability is now available to download and adapt locally. This can be downloaded from [web link 3](#).

## Vaccine Coverage

### HPV Vaccine Coverage Collection 2015/16 AND MenACWY and Td/IPV Vaccine Coverage Collection 2015/16

The deadline for submission of annual 2015/16 vaccine coverage data for both of these schools-based programmes is **Thursday 29 September 2016**. User guides are available for each collection via the following links:

- HPV Vaccine Coverage Collection 2015/16 Local Authority Annual Survey: [web link 11](#)
- MenACWY and Td/IPV Vaccine Coverage Collection 2015/16 Local Authority Annual Survey: [web link 12](#)

Annual vaccine coverage and delivery model information is requested for each Local Authority, via the ImmForm website, for vaccinations administered up to 31 August 2016. Please contact [hpv@phe.gov.uk](mailto:hpv@phe.gov.uk) or [menacwy@phe.gov.uk](mailto:menacwy@phe.gov.uk) if you have any queries about these collections.

# Vaccine Supply

## InterVax BCG Vaccine

A copy of the InterVax BCG vaccine Material Safety Data Sheet (MSDS) is available on the Gov website (see [web link 4](#))

This complements other InterVax BCG vaccine resources available at [web link 5](#).

## Update on Hepatitis B Adult vaccine ordering

GSK have received supply of adult hepatitis B vaccine to the UK and now have supplies in all UK depots. The ordering restrictions applied in May 2016 have now been lifted and normal supply has resumed. For more information on ordering these vaccines visit [web link 6](#) or on 0808 100 9997.

## MenACWY vaccines


There are 2 MenACWY vaccines available: Menveo and Nimenrix.

In England and Wales, the MenACWY vaccine Menveo is available without restriction to all ImmForm accounts. In order to balance central stocks, ordering for the MenACWY vaccine Nimenrix is currently restricted to 5 packs per order per week. Either vaccine can be given to eligible patients.

## Shingles vaccine expiry date and pack change

The shingles vaccine Zostavax is now available for eligible patients in the fourth year of the programme which started on 1 September 2016. Please note that Zostavax currently being issued has a relatively short expiry of December 2016 or January 2017. Please ensure that you do not over order this vaccine and only order enough to meet demand for your next two weeks.

Please ensure that when ordering for Zostavax and other childhood vaccines, the required products are all placed in the same ImmForm order to reduce the number of deliveries which have to be made at this very busy time of year. Earlier in 2016 the Zostavax pack changed slightly and the new cartons, which PHE will start to deliver during October, now show the text 'subcutaneous or intramuscular use' on the front, which is more aligned to the current SPC (please see above image).



## MenB vaccine for at risk patients

The MenB vaccine Bexsero supplied through ImmForm should not be used to vaccinate at risk patients (as described in the Green Book chapter, see [web link 7](#)). Bexsero in a single dose pack is available to purchase privately from the manufacturer, GlaxoSmithKline.

If private supply is unavailable please contact [vaccinesupply@phe.gov.uk](mailto:vaccinesupply@phe.gov.uk) for advice.

## InterVax BCG vaccine availability

The BCG vaccine supplied by InterVax Ltd, Canada and manufactured by BB-NCIPD Ltd, Bulgaria, remains available to order for certain accounts in line with the advice outlined in the BCG Vaccine Update special edition (see [web link 8](#)). Please see PHE webpages ([web link 5](#)) for more information on the use of the InterVax BCG vaccine which has a different presentation to the Statens Serum Institute (SSI) BCG vaccine.

## Use of SSI BCG vaccine batch 114022A

SSI BCG vaccine batch 114022A with a labelled expiry of 29 February 2016, which was extended to 31 August 2016 should no longer be used and any remaining stock of SSI BCG vaccine from batch 114022A should be disposed of in line with local policies and recorded on ImmForm.

## Primary infant vaccine

Ordering for Pediacel remains restricted to 3 doses per order, per week in England. Restrictions are also in place for Wales and Scotland. Infanrix IPV Hib is available to order, with no restriction on volume. Where possible and if local stock allows, it is preferable that the same DTaP/ IPV-Hib containing vaccine be used for all three doses of the primary course. However, vaccination should never be delayed because the vaccine used for previous doses is not known or unavailable.

## PPD2TU

Due to manufacturing delays, orders for PPD2TU (Mantoux) are currently restricted to 1 pack per account per fortnight for NHS customers and closed for private customers.

## PPD10TU

Due to manufacturing delays PPD10TU is not currently available to order. As per the Green Book guidance (see [web link 10](#)) PPD 10TU is recommended if a second Mantoux test is required for clinical diagnostic purposes, and alternative testing may be available.

## Pre-School Booster

The pre-school booster vaccine given to infants from three years four months old will switch from Infanrix IPV to Repevax later in 2016. It is anticipated that ordering for Repevax will open on ImmForm alongside Infanrix IPV in October 2016, with ordering for Infanrix IPV closing several weeks after this. Whilst stocks of Infanrix IPV remain available these should be used first. Both Repevax and Infanrix-IPV are suitable for the pre-school booster vaccination, regardless of the vaccine used for primary vaccination.

As a reminder, Repevax is supplied as a prefilled syringe without needles and manufactured by Sanofi Pasteur MSD.

Repevax is **not for use in the maternal pertussis programme**, for which Boostrix IPV continues to be available.



## All vaccines for the childhood flu immunisation programme are now available to order on ImmForm

The following vaccines are available for the 2016/17 influenza season, and are supplied for the following cohorts:

Vaccine	Pack size	Type	Age indication	Cohort
Fluenz Tetra (LAIV), AstraZeneca UK Ltd	10 dose	Quadrivalent live attenuated	From 24 months to less than 18 years of age	<ul style="list-style-type: none"> <li>All 2, 3 and 4 year olds</li> <li>All children of school years 1, 2 and 3 age</li> <li>All primary school-aged children from previous pilot areas<sup>2</sup></li> <li>All children from 2 years to less than 18 years old in clinical risk groups</li> </ul>
Fluarix Tetra, GSK	Single dose	Quadrivalent inactivated	From 3 years of age	<ul style="list-style-type: none"> <li>Children in the above cohorts aged from 3 years who are contraindicated for Fluenz Tetra and in a clinical risk group</li> </ul>
Inactivated influenza vaccine (split virion) BP, SPMSD	Single dose	Trivalent inactivated	From 6 months of age	<ul style="list-style-type: none"> <li>Children aged 6 months to less than 2 years in a clinical risk group</li> <li>Children aged less than 3 years who are contraindicated for Fluenz Tetra and in a clinical risk group</li> </ul>

<sup>2</sup> Bury, Gateshead, Leicester City and Rutland, Havering and South East Essex

## Controls on LAIV (Fluenz Tetra<sup>®</sup>) ordering

### **For the 2016/17 season, initial ordering controls for Fluenz Tetra<sup>®</sup> are in place for General Practice providers.**

These controls work by allocating an amount of vaccine to each practice, based on the number of eligible patients. They will apply for an initial period, and will be regularly reviewed and updated throughout the season.

During the initial ordering period, this allocation will be set at a level of 35% of eligible patients<sup>3</sup>, which is in line with the average uptake level achieved by general practice nationally last season<sup>4</sup>. This will have the impact of ensuring that all practices can access a substantial proportion of what they might need initially, whilst helping to reduce the amount of vaccine which may go unused if there were no controls in place.

**We stress that 35% is not a target in the initial period, or a level that should automatically be ordered up to if you do not expect to use the vaccine.** The national uptake ambition for 2 to 7 year olds remains at 40-65% by the end of the season, as set out in the 2016/17 flu plan and letter<sup>5</sup>. Advice to hold 2 weeks' worth of stock at any one time still applies.

We understand and acknowledge that there are practices that achieved higher uptake than the average by the end of the last season, and potentially earlier on in the season. If you are one of these practices and you need to access more vaccine before the controls are increased nationally or removed this year, then you can contact the ImmForm helpdesk to discuss your requirements.

**Requests for additional vaccine will be considered on a case by case basis** but please note, this does not mean that practices with previous uptake higher than 35% at the end of the season will be automatically allowed to order more vaccine in the first few weeks. Frontloading of vaccine when it has a very short shelf life cannot be supported and it is important that vaccine already ordered is used before determining the requirement for more. Practices will need to make a strong case for ordering over the set level during the initial period.

The controls have been put in place to manage the national supply across the season, and will be kept under review. It is anticipated that the allocations will be increased as the season progresses. **Changes to controls in-season will be communicated via the ImmForm news item** so please check regularly.

These measures have been taken to ensure that vaccine is available for those that need it and to help the NHS save a significant amount of money.

**At present there are no plans to implement similar controls on school based providers** as last years' data suggests that vaccine ordered was well matched to the vaccine uptake data. However there will be a high level cap on orders for schools, set at 300 packs (or 3,000 doses) per order per week to prevent accidental over-ordering. We recognise that there will be some instances in which school teams require more than this. Where this is the case, you can contact the ImmForm helpdesk directly to discuss your requirements. This cap will also be kept under review throughout the season and changes communicated through the ImmForm news item.

<sup>3</sup> For the initial period of ordering controls, the number of eligible patients has been calculated using the data submitted at the end of the 2015/16 season. Allocations will be updated once 2016/17 cohort data has been received through ImmForm.

<sup>4</sup> There will be a default allocation of 1 pack (10 doses) per week for any general practices who did not submit patient data in 2015/16, but this may be increased on a case by case basis.

<sup>5</sup> [www.gov.uk/government/uploads/system/uploads/attachment\\_data/file/529954/Annual\\_flu\\_letter\\_2016\\_2017.pdf](http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/529954/Annual_flu_letter_2016_2017.pdf)

## Controls on inactivated flu vaccine ordering

Inactivated influenza vaccine (split virion) BP has a cap of 5 doses per order per week. Fluarix Tetra® has a cap of 30 doses per order per week.

These controls will also be regularly reviewed and updates provided through the ImmForm website.

**Please note that these controls are for ENGLAND ONLY.** For information on supply of influenza vaccines in Scotland, Wales and Northern Ireland, please refer to guidance from your respective health departments.

## Fluenz Tetra shelf life

Fluenz Tetra is a live attenuated vaccine and as such has **a very short shelf life**. Please bear this in mind when ordering.

You will be able to place an order **every week** and deliveries will be made weekly alongside your usual deliveries of vaccines. Where possible do not order more than you will need for the next two weeks. This is to minimise vaccine wastage due to the vaccine passing its expiry date before it can be administered to patients.

The vaccine will be available to order throughout the entire flu season to ensure there is in date stock available into the New Year. Subsequent deliveries of vaccine will have later expiry dates of January, March and April.

### **REMEMBER the General Principles for LAIV ordering**

- LAIV is supplied in a 10-dose pack: **1 pack = 10 doses**
- **Order small amounts weekly** and receive weekly deliveries
- Be **realistic** about the amount of vaccine that you expect to need
- Spread your orders over the course of the flu vaccination season – **later ordered stock will have a later expiry date and will last longer**
- Hold no more than 2 weeks stock in your fridge; **local stockpiling can cause delays or restrictions on stock being released to the NHS, and increases the risk of significant loss of stock if there is a cold chain failure in your practice**

## Web links

web link 1	<a href="https://www.gov.uk/government/publications/flu-immunisation-for-early-years-settings-including-child-minders">https://www.gov.uk/government/publications/flu-immunisation-for-early-years-settings-including-child-minders</a>
web link 2	<a href="https://www.gov.uk/government/publications/easy-read-childhood-nasal-flu-leaflet">https://www.gov.uk/government/publications/easy-read-childhood-nasal-flu-leaflet</a>
web link 3	<a href="https://www.gov.uk/government/publications/flu-vaccination-easy-read-invitation-letter-template">https://www.gov.uk/government/publications/flu-vaccination-easy-read-invitation-letter-template</a>
web link 4	<a href="https://www.gov.uk/government/publications/intervax-bcg-vaccine-certificates">https://www.gov.uk/government/publications/intervax-bcg-vaccine-certificates</a>
web link 5	<a href="https://www.gov.uk/government/collections/immunisation#tuberculosis">https://www.gov.uk/government/collections/immunisation#tuberculosis</a>
web link 6	<a href="http://www.vaccines.co.uk">http://www.vaccines.co.uk</a>
web link 7	<a href="https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22">https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22</a>
web link 8	<a href="https://www.gov.uk/government/publications/vaccine-update-issue-247-june-2016-special-edition">https://www.gov.uk/government/publications/vaccine-update-issue-247-june-2016-special-edition</a>
web link 9	<a href="https://www.gov.uk/government/publications/intervax-bcg-vaccine-training-slideset-for-healthcare-professionals">https://www.gov.uk/government/publications/intervax-bcg-vaccine-training-slideset-for-healthcare-professionals</a>
web link 10	<a href="https://www.gov.uk/government/publications/tetanus-the-green-book-chapter-30">https://www.gov.uk/government/publications/tetanus-the-green-book-chapter-30</a>
web link 11	<a href="https://www.gov.uk/government/publications/human-papillomavirus-hpv-vaccine-uptake-data-collection-tool-guidance">https://www.gov.uk/government/publications/human-papillomavirus-hpv-vaccine-uptake-data-collection-tool-guidance</a>
web link 12	<a href="https://www.gov.uk/government/publications/menacwy-and-tdipv-vaccine-uptake-user-guidance">https://www.gov.uk/government/publications/menacwy-and-tdipv-vaccine-uptake-user-guidance</a>